Turkey A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in Azerbaijan; drug shortages resulting from a newly adopted currency-indexed medication supply system, and the surge in upper respiratory tract infections…
Pharma Hungary has long boasted a vibrant, skilled pharmaceutical industry that continues to attract the interest of local and multinational entities alike. This fact was highlighted today at the celebration of GlaxoSmithKline’s incorporation of new technologies and production units at its state-of-the-art Gödöllő Vaccine Facility on the outskirts of Budapest. While GSK’s dynamic…
GSK The general manager of a British pharma giant with over 25 years of presence in Romania discusses how vaccination programs can play a significant role in increasing the cost-effectiveness of the national healthcare system. She also outlines her company’s CSR initiatives to stem the migratory outflow of medical professionals. How have…
GSK GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in the pharmaceutical industry, and the need for the industry and government to approach all discussions with a partnership mentality. Do…
innovation Mexico is one of GSK’s growth engines in Latin America. The VP and general manager for Mexico discusses how the country is increasingly playing a strategic role for the company to get new healthcare products faster to the market by leveraging local R&D. Besides Asia Pacific and Japan,…
R&D Francis del Val, President & Managing Director of GSK, Philippines, talks about his experience working in the pharmaceutical and healthcare sector in the Philippines, and discusses at length the company’s (and industry’s) largest challenge: Employee retention. The growth of the pharmaceutical market, according to IMS Health data, is only set…
Array Eduardo Pinto Leite, Director General of GSK Portugal, talks about the recent Portugal bailout, how its effects pushed GSK to some tough decision, and why he sees a brighter future for the company, and country, despite all the recent economic and market turmoil. You started running this affiliate in 2010,…
government relations In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan University Hospital (NTU)—the first agreement of its kind—a later MoU with Taipei Veterans General Hospital, and a major 2012 collaboration…
GlaxoSmithKline Mexico You worked several years ago in Mexico, and there have been significant changes in the country since then. From your perspective, how did the Mexican pharmaceutical landscape shift over the past few years, and how did that impact GSK’s strategy in the country? Indeed, there have been some important changes…
GlaxoSmithKline (GSK) The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia Pacific region? GSK Asia Pacific is composed of: North East Asia, South East Asia and South Pacific (this includes countries…
See our Cookie Privacy Policy Here